X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aventis Pharma with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs MYLAN (US) - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   MYLAN
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
MYLAN
Dec-14
SANOFI INDIA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs4,5603,867-   
Low Rs4,4002,725-   
Sales per share (Unadj.) Rs1,028.51,324.0-  
Earnings per share (Unadj.) Rs129.0159.5-  
Cash flow per share (Unadj.) Rs186.0256.7-  
Dividends per share (Unadj.) Rs68.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs753.6658.1-  
Shares outstanding (eoy) m23.03378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x4.42.5 175.0%   
Avg P/E ratio x34.720.7 168.1%  
P/CF ratio (eoy) x24.112.8 187.6%  
Price / Book Value ratio x5.95.0 118.7%  
Dividend payout %52.70-   
Avg Mkt Cap Rs m103,1741,247,263 8.3%   
No. of employees `0003.625.0 14.5%   
Total wages/salary Rs m3,5920-   
Avg. sales/employee Rs Th6,537.720,038.0 32.6%   
Avg. wages/employee Rs Th991.40-   
Avg. net profit/employee Rs Th819.82,413.9 34.0%   
INCOME DATA
Net Sales Rs m23,686500,951 4.7%  
Other income Rs m708-2,920 -24.2%   
Total revenues Rs m24,394498,031 4.9%   
Gross profit Rs m5,281124,589 4.2%  
Depreciation Rs m1,31336,793 3.6%   
Interest Rs m1521,608 0.1%   
Profit before tax Rs m4,66163,268 7.4%   
Minority Interest Rs m0-260 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6912,660 63.6%   
Profit after tax Rs m2,97060,348 4.9%  
Gross profit margin %22.324.9 89.6%  
Effective tax rate %36.34.2 862.8%   
Net profit margin %12.512.0 104.1%  
BALANCE SHEET DATA
Current assets Rs m15,673440,402 3.6%   
Current liabilities Rs m6,678344,306 1.9%   
Net working cap to sales %38.019.2 198.0%  
Current ratio x2.31.3 183.5%  
Inventory Days Days7678 97.3%  
Debtors Days Days22107 20.8%  
Net fixed assets Rs m8,098115,894 7.0%   
Share capital Rs m23017,715 1.3%   
"Free" reserves Rs m17,0880-   
Net worth Rs m17,356249,022 7.0%   
Long term debt Rs m0372,014 0.0%   
Total assets Rs m25,4001,003,037 2.5%  
Interest coverage x311.73.9 7,936.3%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.90.5 186.7%   
Return on assets %11.88.2 143.8%  
Return on equity %17.124.2 70.6%  
Return on capital %26.913.6 197.7%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Net fx Rs m2990-   
CASH FLOW
From Operations Rs m3,22665,850 4.9%  
From Investments Rs m-1,555-51,931 3.0%  
From Financial Activity Rs m-1,818-17,352 10.5%  
Net Cashflow Rs m-147-3,433 4.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.89 Rs / USD

Compare SANOFI INDIA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare SANOFI INDIA With: BIOCON LTD  WOCKHARDT LTD.  SHASUN PHARMA  ALKEM LABORATORIES  DIVIS LABORATORIES  



Today's Market

Sensex Continues Momentum; Metal Sector Up 2.5%(11:30 am)

After opening the day on a positive note, stock markets in India have continued their momentum. Sectoral indices are trading on a positive note with stocks in the metal sector.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 23, 2018 12:49 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - TTK HEALTHCARE COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS